Veliparib dihydrochloride

1 1

Selleck Chemicals

E7366-5MG

€193,00 EUR
€193,00 EUR
Sale Sold out
Shipping calculated at checkout.
Size
View full details

Veliparib dihydrochloride is an inhibitor of PARP used in studies of DNA Damage Response. It is especially relevant in cancer and dna damage / repair models, where defined compound exposure can be linked to checkpoint activation, DNA repair, and genome-stability control.

By inhibiting PARP, Veliparib dihydrochloride can be used to examine checkpoint activation, DNA repair, and genome-stability control. The enzyme annotation adds relevance to enzyme-activity assays, substrate-conversion studies, and mechanism profiling, together with downstream-response mapping in the same experimental setting. In cancer and dna damage / repair models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

  • Target-focused assays involving PARP
  • Pathway perturbation studies connected to DNA Damage Response
  • Concentration-response inhibition and target-dependence studies
  • Enzyme-activity assays, substrate-conversion studies, and mechanism profiling

Overall, Veliparib dihydrochloride is appropriate when a defined chemical perturbant is needed to connect PARP with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in cancer and dna damage / repair models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.

Targets:
PARP
Target Class:
Enzyme
Pathways:
DNA Damage Response
Research Area:
Cancer • DNA Damage / Repair
CAS No.:
912445-05-7
Molecular Weight:
317.21
Formula:
C₁₃H₁₆N₄O·2ClH
Storage Temperature:
-20°C

For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.

The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.